[go: up one dir, main page]

EE05662B1 - Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine - Google Patents

Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Info

Publication number
EE05662B1
EE05662B1 EEP200100549A EEP200100549A EE05662B1 EE 05662 B1 EE05662 B1 EE 05662B1 EE P200100549 A EEP200100549 A EE P200100549A EE P200100549 A EEP200100549 A EE P200100549A EE 05662 B1 EE05662 B1 EE 05662B1
Authority
EE
Estonia
Prior art keywords
composition
hiku
antagonist
sub
treating fibrosis
Prior art date
Application number
EEP200100549A
Other languages
English (en)
Estonian (et)
Inventor
Gotwals Philip
R. Lobb Roy
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200100549A publication Critical patent/EE200100549A/xx
Publication of EE05662B1 publication Critical patent/EE05662B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100549A 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine EE05662B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (2)

Publication Number Publication Date
EE200100549A EE200100549A (et) 2002-12-16
EE05662B1 true EE05662B1 (et) 2013-06-17

Family

ID=26828876

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100549A EE05662B1 (et) 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Country Status (31)

Country Link
US (3) US6652856B2 (xx)
EP (1) EP1173201B1 (xx)
JP (3) JP5483515B2 (xx)
KR (3) KR20070102760A (xx)
CN (3) CN100360183C (xx)
AT (1) ATE298249T1 (xx)
AU (1) AU783054B2 (xx)
BG (2) BG65578B1 (xx)
BR (1) BR0010669A (xx)
CA (1) CA2370814C (xx)
CY (1) CY1106046T1 (xx)
CZ (1) CZ301636B6 (xx)
DE (1) DE60020955T2 (xx)
DK (1) DK1173201T3 (xx)
EA (1) EA006681B1 (xx)
EE (1) EE05662B1 (xx)
ES (1) ES2243259T3 (xx)
GE (1) GEP20063844B (xx)
HK (1) HK1041452B (xx)
HU (1) HU226383B1 (xx)
IL (5) IL145898A0 (xx)
IS (1) IS2259B (xx)
MX (1) MXPA01010612A (xx)
NO (1) NO330221B1 (xx)
NZ (2) NZ541431A (xx)
PL (1) PL198975B1 (xx)
PT (1) PT1173201E (xx)
RS (2) RS20080471A (xx)
SK (1) SK287328B6 (xx)
TR (1) TR200200027T2 (xx)
WO (1) WO2000064474A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298249T1 (de) * 1999-04-22 2005-07-15 Biogen Idec Inc Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
SK17232001A3 (sk) * 1999-06-01 2002-09-10 Biogen, Inc. Použitie blokujúcej monoklonálnej protilátky proti VLA-1 na výrobu farmaceutickej kompozície na liečenie zápalových ochorení
EP1183040B1 (en) * 1999-06-08 2004-12-01 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog signalling pathway
US20020013300A1 (en) * 2000-03-17 2002-01-31 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
YU80903A (sh) * 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP5037134B2 (ja) * 2003-10-17 2012-09-26 レハブ アル−ジャマル 組織修復
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
CA2652815C (en) * 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
DK2185198T3 (en) 2007-08-02 2015-04-20 Gilead Biologics Inc LOX AND LOXL2 INHIBITORS AND APPLICATIONS THEREOF
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
JP5733546B2 (ja) * 2012-03-28 2015-06-10 国立大学法人広島大学 インテグリンα８β１の機能を阻害する事による線維化の抑制
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
EP3755723A4 (en) * 2018-02-23 2021-12-22 Chugai Seiyaku Kabushiki Kaisha CROSS SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1995019790A1 (en) * 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5855888A (en) * 1994-04-26 1999-01-05 Kanebo, Ltd. Drug for the treatment of rheumatoid arthritis
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
DE69840113D1 (de) * 1997-08-08 2008-11-20 Univ California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
ATE298249T1 (de) * 1999-04-22 2005-07-15 Biogen Idec Inc Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
IS6105A (is) 2001-10-11
US20020182213A1 (en) 2002-12-05
AU4480000A (en) 2000-11-10
HUP0201015A2 (hu) 2002-07-29
NZ541431A (en) 2008-01-31
BG106118A (en) 2002-05-31
IL182908A (en) 2010-11-30
EE200100549A (et) 2002-12-16
US20050281818A1 (en) 2005-12-22
HK1076379A1 (zh) 2006-01-20
DE60020955D1 (de) 2005-07-28
NO330221B1 (no) 2011-03-07
YU74901A (sh) 2004-07-15
KR20020000221A (ko) 2002-01-05
EA006681B1 (ru) 2006-02-24
IL206830A (en) 2013-06-27
BG66149B1 (bg) 2011-08-31
JP5483515B2 (ja) 2014-05-07
WO2000064474A1 (en) 2000-11-02
CY1106046T1 (el) 2011-04-06
US6652856B2 (en) 2003-11-25
WO2000064474A8 (en) 2001-04-05
DK1173201T3 (da) 2005-09-12
EP1173201B1 (en) 2005-06-22
PT1173201E (pt) 2005-08-31
GEP20063844B (en) 2006-06-12
CA2370814A1 (en) 2000-11-02
MXPA01010612A (es) 2003-09-04
HU226383B1 (hu) 2008-10-28
CN100360183C (zh) 2008-01-09
SK287328B6 (sk) 2010-07-07
DE60020955T2 (de) 2006-05-11
CA2370814C (en) 2010-07-06
RS50086B (sr) 2009-01-22
CN1596979A (zh) 2005-03-23
KR100837715B1 (ko) 2008-06-13
IL206829A0 (en) 2010-12-30
IL182908A0 (en) 2007-08-19
CZ301636B6 (cs) 2010-05-12
BR0010669A (pt) 2002-02-19
AU783054B2 (en) 2005-09-22
EP1173201A1 (en) 2002-01-23
NZ515053A (en) 2004-02-27
CN1191860C (zh) 2005-03-09
TR200200027T2 (tr) 2002-07-22
HUP0201015A3 (en) 2004-12-28
CN1332714C (zh) 2007-08-22
KR20070102760A (ko) 2007-10-19
NO20015122L (no) 2001-12-21
JP2007182453A (ja) 2007-07-19
SK15202001A3 (sk) 2002-09-10
IL145898A (en) 2007-07-24
HK1041452A1 (en) 2002-07-12
CZ20013754A3 (cs) 2002-07-17
US20040037827A1 (en) 2004-02-26
CN1679935A (zh) 2005-10-12
ATE298249T1 (de) 2005-07-15
NO20015122D0 (no) 2001-10-19
JP2014065747A (ja) 2014-04-17
IL206830A0 (en) 2010-12-30
KR100746522B1 (ko) 2007-08-07
PL351916A1 (en) 2003-06-30
ES2243259T3 (es) 2005-12-01
CN1356911A (zh) 2002-07-03
EA200101116A1 (ru) 2002-04-25
IL145898A0 (en) 2002-07-25
PL198975B1 (pl) 2008-08-29
RS20080471A (sr) 2010-12-31
JP2002542300A (ja) 2002-12-10
HK1041452B (en) 2005-10-14
IL206829A (en) 2013-06-27
KR20070050979A (ko) 2007-05-16
BG110115A (en) 2008-12-30
IS2259B (is) 2007-06-15
BG65578B1 (bg) 2009-01-30

Similar Documents

Publication Publication Date Title
EE05662B1 (et) Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
DE60119945D1 (de) Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
LU93274I2 (fr) Elotuzumab
BR9812886A (pt) Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
EA200100041A1 (ru) Способ лечения
EP1666063A3 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
FI20001459L (fi) Briketti, menetelmä sen valmistamiseksi ja sen käyttö

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20150421